S
Sue Fletcher
Researcher at University of Western Australia
Publications - 192
Citations - 7472
Sue Fletcher is an academic researcher from University of Western Australia. The author has contributed to research in topics: Exon & Exon skipping. The author has an hindex of 37, co-authored 180 publications receiving 6681 citations. Previous affiliations of Sue Fletcher include University of Leicester & University of Melbourne.
Papers
More filters
Journal ArticleDOI
Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
TL;DR: Intravenous magnesium sulphate treatment is a simple, safe, and widely applicable treatment and its efficacy in reducing early mortality of myocardial infarction is comparable to but independent of, that of thrombolytic or antiplatelet therapy.
Journal ArticleDOI
Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements
TL;DR: Recent insights into the regulatory roles of the untranslated gene regions and non-coding RNAs in the control of complex gene expression are discussed, as well as the implications of this in terms of organism complexity and evolution.
Journal ArticleDOI
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Qi Long Lu,Christopher J. Mann,Fang Lou,George Bou-Gharios,Glenn E. Morris,Shao-An Xue,Sue Fletcher,Terence A. Partridge,Stephen D. Wilton +8 more
TL;DR: The data establishes the realistic practicality of an approach that is applicable, in principle, to a majority of cases of severe dystrophinopathy, and proves the power of splicing around mutations to promote skipping of the mutated exon.
Journal ArticleDOI
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Christopher J. Mann,K. Honeyman,Andy J. Cheng,Tina Ly,Frances Lloyd,Sue Fletcher,Jennifer E. Morgan,T. Partridge,Stephen D. Wilton +8 more
TL;DR: This approach should reduce the severity of DMD by allowing a dystrophic gene transcript to be modified, such that it can be translated into a Becker-dystrophin-like protein.
Journal ArticleDOI
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
Rita Mejzini,Loren L. Flynn,Loren L. Flynn,Ianthe Pitout,Ianthe Pitout,Sue Fletcher,Sue Fletcher,Steve D. Wilton,Steve D. Wilton,P.A. Akkari,P.A. Akkari +10 more
TL;DR: The genetic basis of ALS is reviewed, highlighting factors that have contributed to the elusiveness of genetic heritability and future directions for research that may lead to effective treatment strategies outlined.